Glaxosmithkline Intellectual Property Development Limited

Shanghai Jemincare Pharmaceuticals Co., Ltd.

Jiangxi Jemincare Group Co., Ltd.

Gasherbrum Bio, Inc.

Genentech, Inc.

Weiqiang Xing

Haibing Guo

Jianbiao Peng

Hongfu Lu

Feng Ren

Xichen Lin

Hui Lei

Haizhen Zhang

Baowei Zhao

Yingxia Sang

Qinghua Meng

Andrew Jennings

Yang Zhan

Baojian Qi

Xiao Ding

Yongcong Lv

Zehong Wan

Qian Liu

Hailong Wang

Yun Jin

Luigi Piero Stasi

Provided are a protein degradation agent compound preparation method and application; specifically, provided are the compound represented by formula (I) and a pharmacologically acceptable salt thereof, and an application of said compound in the degradation of androgen receptor (AR).

Protein degradation agent compound preparation method and application

Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.

Phthalazinone compound, and preparation method therefor and medical use thereof

This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Heterocyclic GLP-1 agonists

Relating to a compound represented by formula (I) and a pharmaceutically acceptable salt of the compound, and an application of the compound as an S1P1 agonist.

Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative

This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.

Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved. 

Compounds for inhibiting LRRK2 kinase activity

Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

Substituted fused pyrazole compounds and their use as LRRK2 inhibitors

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Compounds

Growing community of inventors

Shanghai, China

Weiqiang Xing